California State Teachers Retirement System Acquires 5,632 Shares of Illumina, Inc. (NASDAQ:ILMN)

California State Teachers Retirement System grew its holdings in Illumina, Inc. (NASDAQ:ILMN – Get Rating) by 2.1% in the 3rd quarter, Holdings Channel reports. The fund owned 272,359 shares of the life sciences company’s stock after purchasing an additional 5,632 shares during the quarter. California State Teachers Retirement System’s holdings in Illumina were worth $51,963,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of ILMN. Twin Tree Management LP bought a new position in Illumina in the third quarter worth $1,147,000. M&G Investment Management Ltd. lifted its position in Illumina by 12.3% in the second quarter. M&G Investment Management Ltd. now owns 105,825 shares of the life sciences company’s stock worth $19,472,000 after purchasing an additional 11,555 shares during the period. Vanguard Personalized Indexing Management LLC lifted its position in Illumina by 31.5% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 5,437 shares of the life sciences company’s stock worth $1,002,000 after purchasing an additional 1,302 shares during the period. Alaethes Wealth LLC lifted its position in Illumina by 19.5% in the second quarter. Alaethes Wealth LLC now owns 3,791 shares of the life sciences company’s stock worth $699,000 after purchasing an additional 619 shares during the period. Finally, Amalgamated Bank lifted its position in Illumina by 1.1% in the third quarter. Amalgamated Bank now owns 39,880 shares of the life sciences company’s stock worth $7,609,000 after purchasing an additional 452 shares during the period. 87.97% of the stock is owned by institutional investors.

Illumina Price Performance

Shares of ILMN stock opened at $224.95 on Friday. The stock has a 50-day moving average price of $208.40 and a 200 day moving average price of $208.60. The company has a quick ratio of 1.08, a current ratio of 1.28 and a debt-to-equity ratio of 0.23. The firm has a market cap of $35.54 billion, a price-to-earnings ratio of -8.03, a PEG ratio of 8.27 and a beta of 1.15. Illumina, Inc. has a 12 month low of $173.45 and a 12 month high of $371.16.

Illumina (NASDAQ:ILMN – Get Rating) last announced its quarterly earnings data on Tuesday, February 7th. The life sciences company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.11). The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a positive return on equity of 3.79% and a negative net margin of 96.12%. Illumina’s revenue for the quarter was down 9.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.75 earnings per share. Research analysts expect that Illumina, Inc. will post 1.41 EPS for the current year.

Insider Buying and Selling

In other Illumina news, SVP Susan H. Tousi sold 500 shares of the firm’s stock in a transaction dated Friday, January 6th. The stock was sold at an average price of $204.58, for a total transaction of $102,290.00. Following the transaction, the senior vice president now owns 38,662 shares in the company, valued at $7,909,471.96. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Illumina news, SVP Susan H. Tousi sold 500 shares of the firm’s stock in a transaction dated Friday, January 6th. The stock was sold at an average price of $204.58, for a total transaction of $102,290.00. Following the transaction, the senior vice president now owns 38,662 shares in the company, valued at $7,909,471.96. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Aimee L. Hoyt sold 871 shares of the firm’s stock in a transaction dated Monday, January 9th. The stock was sold at an average price of $205.57, for a total value of $179,051.47. Following the transaction, the senior vice president now owns 2,796 shares in the company, valued at approximately $574,773.72. The disclosure for this sale can be found here. Insiders sold a total of 11,186 shares of company stock worth $2,255,837 over the last three months. 0.13% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Scotiabank assumed coverage on Illumina in a research report on Wednesday, January 4th. They issued a “sector perform” rating and a $216.00 target price for the company. Bank of America increased their price objective on Illumina from $210.00 to $230.00 in a research note on Wednesday, February 8th. Piper Sandler reiterated an “overweight” rating and set a $290.00 price objective on shares of Illumina in a research note on Wednesday, February 8th. SVB Leerink increased their price objective on Illumina from $249.00 to $250.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 8th. Finally, UBS Group dropped their price objective on Illumina from $255.00 to $240.00 and set a “neutral” rating for the company in a research note on Tuesday, February 14th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $249.40.

Illumina Profile

(Get Rating)

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions.